Australia Markets close in 5 hrs 38 mins

Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at LifeSci Partners’ virtual Immunology and Inflammation (I&I) Symposium, taking place May 10th-11th, 2022.

LifeSci Partners Immunology and Inflammation Symposium fireside chat details:


Tuesday, May 10th, 2022


12:00pm Eastern Time


The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). Designed to be optimized as a simple, subcutaneous injection with dosing that can be tailored based on disease severity and stage, batoclimab may reduce immunoglobin G (IgG) antibodies that cause inflammation and disease. For additional information on the Company, please visit


Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting